Clémence David's research while affiliated with Université Paris-Saclay and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publication (1)
Background
Anti-PD-(L)1 treatment is indicated for patients with mismatch repair-deficient (MMRD) tumors, regardless of tumor origin. However, the response rate is highly heterogeneous across MMRD tumors. The objective of the study is to find a score that predicts anti-PD-(L)1 response in patients with MMRD tumors.Methods
Sixty-one patients with va...
Citations
... People with a higher total tumor burden tend to have a worse prognosis and a lower likelihood of surviving compared with those with a lower total tumor burden. [7][8][9] Patient-centered parameters also appear to be prognostic for survival. Therefore, body mass index (BMI) was higher in patients with melanoma treated by anti-PD-1 checkpoint inhibitors who had a better survival 10 or had early acute limiting toxicity. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/622257059663876-1525369052808_Q64/Laetitia-Nebot.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/474698992623617-1490188467675_Q64/Littisha-Lawrance.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272493420216361-1441978902767_Q64/Antoine-Hollebecque.jpg)
